Descrizione Clinica
Neoiodarsolo os 10fl 15ml Laboratori Baldacci
NEOIODARS
active ingredients
each bottle contains: Active ingredients: L-arginine L-2 pyrrolidon-5-carboxyl mg 300; cyanocobalamin mcg 50; Excipients with known effects: sucrose mg 4000; sorbitol mg 1500; methyl p-hydroxybenzoate mg 16,5. For the full list of excipients, see paragraph 6.1.Excellent
Sacrosis; sorbitol; p-hydroxybenzoate methyl; lemon aroma; demineralized water.Therapeutic indications
States of defedance and convalescence.Contraindications
Hypersensitivity to active ingredients or any of the excipients listed in paragraph 6.1. Generally contraindicated in pregnancy and nursing.Population
The product should be taken orally, as such or diluted in little water. Adults: 3 bottles per day; Children: up to 6 years, a bottle per day; over 6 years, two bottles per day. Do not exceed the recommended doses.Conservation
None.Warnings
The oral solution contains sucrose and sorbitol. Patients with rare hereditary problems of fructose intolerance, glucose-galactosis mal absorption, or isomaltase sucrasis failure, should not take this medicine. The product contains sucrose in the quantities indicated, of this to be taken into account in the case of diabetes or hypocaloric diets. In addition, sucrose can be harmful to teeth. For the presence of p-hydroxybenzoate methyl allergic reactions (also delayed) can occur. Keep out of reach of children.Interactions
Not known.Effects
No side effects related to the use of the product have been reported. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address http://www.agenziafarmaco.gov.it/it/responsabili.Overdosing
No overdose cases have ever been reported with Neoiodarsolo.in pregnancy and breastfeeding the safety of Neoiodarsolo is not demonstrated; therefore, the product should be administered in cases of absolute necessity when, according to the doctor, potential benefits exceed the possible risks.
Source: Farmadati
